PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin
and EPA delivered separately as co-administered products (metformin hydrochloride or
Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin
eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to
evaluate the safety and tolerability of single and repeat single doses of TP-101.